Partial Reprogramming and Cellular Age Reversal

The Yamanaka factor partial reprogramming field reached clinical relevance in 2025. Research from the Altos Labs and Calico consortium demonstrated that brief, controlled expression of Oct4, Sox2, and Klf4 (three of the four Yamanaka factors) in aged mice reversed epigenetic age by 40-60% as measured by methylation clocks, while avoiding tumor formation that plagued earlier complete reprogramming attempts. The breakthrough: a time-limited delivery system using lipid nanoparticles that degrades in 72 hours, producing reversible rejuvenation without permanent genetic modification. A non-human primate trial showed similar epigenetic age reversal without adverse effects at 6-month follow-up. Human safety trials were approved in Singapore and the UK for progeria patients. This is not yet proven life extension — epigenetic clocks are proxies, not direct lifespan measurements — but the biological plausibility is the strongest it has ever been.